Acelyrin, Inc. (NASDAQ:SLRN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Acelyrin, Inc. (NASDAQ:SLRN) has been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $11.50.

Several equities analysts have recently commented on the company. Wells Fargo & Company increased their target price on Acelyrin from $13.00 to $15.00 and gave the company an “overweight” rating in a research note on Wednesday, October 16th. HC Wainwright raised their price objective on shares of Acelyrin from $6.00 to $8.00 and gave the stock a “neutral” rating in a report on Thursday, November 14th. Piper Sandler dropped their target price on shares of Acelyrin from $68.00 to $20.00 and set an “overweight” rating for the company in a research report on Wednesday, August 14th. Finally, Morgan Stanley reduced their price target on shares of Acelyrin from $13.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Monday, August 19th.

Acelyrin Stock Performance

NASDAQ:SLRN opened at $4.64 on Friday. The stock has a market cap of $465.51 million, a price-to-earnings ratio of -1.89 and a beta of 1.98. Acelyrin has a one year low of $3.36 and a one year high of $8.89. The business’s 50-day simple moving average is $5.40 and its 200 day simple moving average is $5.03.

Institutional Trading of Acelyrin

A number of institutional investors and hedge funds have recently modified their holdings of the business. Virtu Financial LLC acquired a new position in shares of Acelyrin in the 3rd quarter valued at about $50,000. Barclays PLC boosted its stake in Acelyrin by 208.8% in the third quarter. Barclays PLC now owns 96,408 shares of the company’s stock valued at $475,000 after acquiring an additional 65,188 shares during the period. Geode Capital Management LLC boosted its stake in Acelyrin by 30.8% in the third quarter. Geode Capital Management LLC now owns 1,651,614 shares of the company’s stock valued at $8,144,000 after acquiring an additional 388,631 shares during the period. Public Employees Retirement System of Ohio grew its holdings in shares of Acelyrin by 54.6% during the third quarter. Public Employees Retirement System of Ohio now owns 102,347 shares of the company’s stock valued at $505,000 after purchasing an additional 36,154 shares during the last quarter. Finally, Virtus Investment Advisers Inc. acquired a new stake in shares of Acelyrin during the 3rd quarter worth approximately $176,000. 87.31% of the stock is owned by institutional investors and hedge funds.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.